Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer

Key Points

• To evaluate the effectiveness of trifluridine–tipiracil with and without bevacizumab in patients with metastatic colorectal cancer (mCRC).
• Conducted a real-world observational study in the U.S.
• Compared rwOS between patients receiving FTD-TPI alone and those receiving FTD-TPI+bev.
• Assessed alignment of findings with the SUNLIGHT clinical trial.
• FTD-TPI+bev was associated with longer real-world overall survival (rwOS) compared to FTD-TPI alone.
• Findings were consistent with the results of the SUNLIGHT clinical trial.